Brief: Pepgen Announces Pricing Of $80.1 Mln Common Stock Offering
Brief: Pepgen Announces First Patient Dosed In Trial For Duchenne Muscular Dystrophy Treatment
Brief: PepGen Q3 Net Income USD -23.29 Million
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius
U.S. STOCKS ON THE MOVE-Scholar Rock, Target, LL Flooring
U.S. STOCKS ON THE MOVE-First Solar, Genetron, Viasat
U.S. STOCKS ON THE MOVE-Albemarle, Delta, OpGen
PepGen rises as US FDA lifts clinical hold on genetic disorder drug study
Brief: PepGen Inc. Announces FDA Has Lifted The Clinical Hold On Its Investigational New Drug Application
Brief: Pepgen Presents Preclinical Data Supporting Co's Enhanced Delivery Oligonucleotide Platform And Pgn-Edodm1 Program
Brief: PepGen Reports Second Quarter 2023 Financial Results
U.S. RESEARCH ROUNDUP-Catalent, Estee Lauder Companies, Marqeta
Brief: PepGen Inc Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
PepGen falls after update for genetic disorder drug trial
Brief: PepGen Inc Files For Mixed Shelf Of Up To $300 Mln
Brief: PepGen Inc. Announces Clinical Hold In U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1
Brief: Pepgen Announces Clearance By Health Canada Of CTA For PGN-Edo51 To Begin The Phase 2 Clinical Trial
Brief: Pepgen Reports Q1 2023 Financial Results And Recent Corporate Developments
Brief: PepGen Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Corporate Developments